Dextramer® CMV Kit - In Vitro Diagnostics

Identify Patients at Risk of CMV Infection 

60 to 80% of transplant patients worldwide have been exposed to cytomegalovirus (CMV). In these patients, CMV can cause significant morbidity and mortality following transplantation due to suppression of cell-mediated immunity. CD8+ T cells are critical in the control of CMV. Indeed, post-transplant immune reconstitution of CMV-specific CD8+ T cells is crucial to control CMV infection and prevent CMV diseases.

Current treatment of CMV is prophylactic or based on early detection of CMV virus load followed by preemptive anti viral treatment [1]. Anti viral drugs are effective, but also expensive and burdened by potential toxicity such as nephrotoxicity and peripheral blood cytopenia.

Refine CMV Management

Delayed recovery of CMV-specific T cells is found to be associated with recurrent CMV infection and CMV disease [2-5]. Several clinical trials have demonstrated the utility of using the number of CMV-specific CD8+ T cells as a predictor of immune resistance to CMV post Hematopoetic Stem Cell Transplantation (HSCT). Initiating anti-viral therapy based on detection of virus load alone may result in unnecessary treatment of patients who would never progress to CMV disease because they have sufficient CMV-specific T-cell immunity to effectively control the virus.

The Dextramer® CMV Kit can enumerate CMV-specific CD8+ T cells in whole blood by flow cytometry [6]. The Dextramer CMV Kit is indicated for assessment of CMV-specific immune status and risk of CMV reactivation in adult HSCT recipients following immunosuppression and used in conjuction with other laboratory and clinical findings [7-8]. The kit cannot be used for measuring CMV infection or disease.

Read more about the Dextramer CMV Kit in a recently published study on HSCT patients.

Dextramer® CMV Kit

Cat. No Content Regulatory Status Package Insert


CMV-specific Dextramer® reagents: 

Negative control Dextramer® reagent

For in vitro diagnostic use in EU



CMV-specific Dextramer® reagents: 

Negative control Dextramer® reagent

Antibodies: Anti-CD8, Anti-CD3, Anti-CD4

For in vitro diagnostics use in US*


* K153538 510(k) premarket notification. 

Related Products

Besides Dextramer CMV Kits, you can get the individual CMV-specific Dextramer reagents as IVD reagents in EU and ASR reagents in US, please see Clinical Research.

How to Order the Dextramer CMV Kit?

Send an e-mail to specifying cat. no. 


1. Badshah C. et al. . NEJM. 2017; 1-12. Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.

2. Cwynarski K, et al. Direct visualization of cytomegalovirus-specific T cell reconstitution after allogeneic stem cell transplantation. Blood. 2001;97(5):1232-40.

3. Gratama JW, et al. Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study. Blood. 2010;116(10):1655-62.

4. Gratama JW, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell depleted stem cell grafts and after transplantation may identify patients at risk of progressive CMV infection. Blood. 2001;98(5): 1358-64.

5. Borcher et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS One. 2012;7(12)

6. Tario J, et al. Dextramer Reagents are Effective Tools for Quantifying CMV Antigen-Specific T Cells from Peripheral Blood Samples. Cytometry B Clin Cytom. 2014;
88(1): 6–20.

7. TF1000.07 Dextramer CMV Kit Package Insert US (IVD), Immudex.

8. TF1010.07 Dextramer CMV Kit Package Insert EU (CE-IVD), Immudex.

Contact Us

Ordering: +45 29 13 42 24
Main: +45 31 10 91 91
Fax: +45 77 31 15 09
CVR/VAT no. 31348854

Technical Support